Siglec-2/CD22 Protein, Mouse (HEK293, His)

Siglec-2/CD22 is a B cell surface receptor that mediates B cell interactions and is involved in B cell localization within lymphoid tissues. It selectively binds α-2,6-linked sialic acids, including CD45, and its sialic acid recognition site may be regulated by cis interactions. Siglec-2/CD22 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-6*His labeled tag.

Siglec-2/CD22 protein functions as a mediator of B-cell interactions and is potentially involved in the localization of B-cells within lymphoid tissues. This protein selectively binds to sialylated glycoproteins, with a preference for alpha-2,6-linked sialic acid, and one of its binding partners is CD45. The recognition site for sialic acid can be masked through cis interactions with sialic acids on the same cell surface. Upon ligand-induced tyrosine phosphorylation during immune responses, Siglec-2/CD22 is implicated in the regulation of B-cell antigen receptor signaling. It plays a dual role in signaling, positively regulating interactions with Src family tyrosine kinases and potentially acting as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains. This recruitment blocks signal transduction through the dephosphorylation of signaling molecules. In molecular interactions, Siglec-2/CD22 associates with proteins such as LYN, SYK, PIK3R1/PIK3R2, PLCG1, SHC1, INPP5D, and GRB2 upon phosphorylation, suggesting its involvement in complex signaling networks that modulate B-cell responses.

Measured by the ability of the immobilized protein to support the adhesion of Jurkat human T-lymphocyte leukemia cells. The ED₅₀ this effect is 0.6816 μg/mL, corresponding to a specific activity is 1.467×10³ units/mg

• 
  Measured by the ability of the immobilized protein to support the adhesion of Jurkat human T-lymphocyte leukemia cells. The ED₅₀ this effect is 0.6816 μg/mL, corresponding to a specific activity is 1.467×10³ units/mg.

Mouse

HEK293

C-6*His

P35329-1 (S22-P702)

12483  [NCBI]

Partial

SANDWTVDHPQTLFAWEGACIRIPCKYKTPLPKARLDNILLFQNYEFDKATKKFTGTVLYNATKTEKDPESELYLSKQGRVTFLGNRIDNCTLKIHPIRANDSGNLGLRMTAGTERWMEPIHLNVSEKPFQPYIQMPSEIRESQSVTLTCGLNFSCFGYDILLKWFLEDSEITSITSSVTSITSSVTSSIKNVYTESKLTFQPKWTDHGKSVKCQVQHSSKVLSERTVRLDVKYTPKLEIKVNPTEVEKNNSVTMTCRVNSSNPKLRTVAVSWFKDGRPLEDQELEQEQQMSKLILHSVTKDMRGKYRCQASNDIGPGESEEVELTVHYAPEPSRVHIYPSPAEEGQSVELICESLASPSATNYTWYHNRKPIPGDTQEKLRIPKVSPWHAGNYSCLAENRLGHGKIDQEAKLDVHYAPKAVTTVIQSFTPILEGDSVTLVCRYNSSNPDVTSYRWNPQGSGSVLKPGVLRIQKVTWDSMPVSCAACNHKCSWALPVILNVHYAPRDVKVLKVSPASEIRAGQRVLLQCDFAESNPAEVRFFWKKNGSLVQEGRYLSFGSVSPEDSGNYNCMVNNSIGETLSQAWNLQVLYAPRRLRVSISPGDHVMEGKKATLSCESDANPPISQYTWFDSSGQDLHSSGQKLRLEPLEVQHTGSYRCKGTNGIGTGESPPSTLTVYYSP

Approximately 100 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.

• 
  ≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.22 μm filtered solution of 50 mM Tris-HCl, 300 mM NaCl, pH 7.4.
Note: For SPR assay, please replace the buffer. Primary amine components (e.g., Tris, imidazole) can affect protein-coupled chips.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.